Not only a therapeutic target; mTOR in Hodgkin lymphoma and acute lymphoblastic leukemia
IntroductionThe mechanistic/mammalian target of rapamycin (mTOR) is a serine/threonine kinase, which is downregulated or upregulated and is implicated in different types of cancer including hematologic neoplasms, skin prostate, and head and neck cancer.AimThe aim of this study was to explore the cur...
Main Authors: | Miguel Enrique Cuéllar Mendoza, Francisco Raúl Chávez Sánchez, Elisa María Dorantes Acosta, Ana María Niembro Zúñiga, Rosana Pelayo, Marta Zapata Tarrés |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1304605/full |
Similar Items
-
Recent advances and limitations of mTOR inhibitors in the treatment of cancer
by: Eunus S. Ali, et al.
Published: (2022-09-01) -
The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?
by: Kostas A. Papavassiliou, et al.
Published: (2021-12-01) -
Dysregulation of mTOR Signaling after Brain Ischemia
by: Mario Villa-González, et al.
Published: (2022-03-01) -
MTOR Signaling and Metabolism in Early T Cell Development
by: Guy Werlen, et al.
Published: (2021-05-01) -
Alcohol Dependence Modulates Amygdalar mTORC2 and PKCε Expression in a Rodent Model
by: Athirah Hanim, et al.
Published: (2023-07-01)